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ARTICLE
Inhibiting Mycobacterium tuberculosis CoaBC by
targeting an allosteric site
Vitor Mendes 1✉, Simon R. Green2, Joanna C. Evans3, Jeannine Hess 4, Michal Blaszczyk1,
Christina Spry 4, Owain Bryant1, James Cory-Wright1, Daniel S-H. Chan4, Pedro H. M. Torres1, Zhe Wang5,
Navid Nahiyaan5, Sandra O’Neill2, Sebastian Damerow2, John Post2, Tracy Bayliss2, Sasha L. Lynch3,
Anthony G. Coyne 4, Peter C. Ray2, Chris Abell 4, Kyu Y. Rhee 5, Helena I. M. Boshoff 6,
Clifton E. Barry III 3,6, Valerie Mizrahi3, Paul G. Wyatt2 & Tom L. Blundell 1✉
Coenzyme A (CoA) is a fundamental co-factor for all life, involved in numerous metabolic
pathways and cellular processes, and its biosynthetic pathway has raised substantial interest
as a drug target against multiple pathogens including Mycobacterium tuberculosis. The bio-
synthesis of CoA is performed in five steps, with the second and third steps being catalysed
in the vast majority of prokaryotes, including M. tuberculosis, by a single bifunctional protein,
CoaBC. Depletion of CoaBC was found to be bactericidal inM. tuberculosis. Here we report the
first structure of a full-length CoaBC, from the model organism Mycobacterium smegmatis,
describe how it is organised as a dodecamer and regulated by CoA thioesters. A high-
throughput biochemical screen focusing on CoaB identified two inhibitors with different
chemical scaffolds. Hit expansion led to the discovery of potent and selective inhibitors of
M. tuberculosis CoaB, which we show to bind to a cryptic allosteric site within CoaB.
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Tuberculosis (TB) is the most prevalent and deadly infec-tious disease worldwide and remains a global epidemic.Despite the availability of treatment, this disease, caused by
Mycobacterium tuberculosis, still claims 1.5 million lives each
year1. Current treatment regimens are long, which presents an
obstacle for patient adherence and imposes a heavy social and
economic burden on countries with a high incidence of TB. It is
therefore critical to explore novel targets and find new and more
effective drugs to combat this disease.
Coenzyme A (CoA) is an essential and ubiquitous co-factor
involved in numerous metabolic pathways with a large number of
different enzymes requiring it for their activity2. CoA is essential
for the synthesis of phospholipids, fatty acids, polyketides and
non-ribosomal peptides, for the operation of the tricarboxylic
acid cycle and in the degradation of lipids3. The importance of
CoA for essential post-translational modifications of proteins is
also well established in both eukaryotes and prokaryotes, with
various proteins post-translationally modified by thioester deri-
vatives of CoA (acylation) or CoA itself (phosphopantetheinyla-
tion and CoAlation), while several other post-translational
modifications depend indirectly on CoA through the mevalonate
pathway4–7. Furthermore, dephospho-CoA, an intermediate of
the CoA pathway, is incorporated into some RNA transcripts
during transcription initiation thereby serving as a non-canonical
transcription initiating nucleotide8. These RNA modifications
have functional consequences and occur in both eukaryotes and
bacteria8. In M. tuberculosis, CoA plays a pivotal role in the
biosynthesis of complex lipids that are crucial components of the
cell wall and required for pathogenicity9. It is also needed for the
degradation of lipids, including cholesterol, which are the primary
source of energy for this organism during infection10,11. Given its
ubiquitous nature, wide metabolic and functional impact of its
inhibition, and lack of sequence conservation between prokar-
yotes and humans, the CoA pathway is therefore an attractive
pathway for drug discovery for many different infectious diseases,
including TB.
The biosynthesis of CoA from pantothenic acid (vitamin B5) is
performed in five steps (Fig. 1), sequentially catalysed by the
enzymes pantothenate kinase (CoaA, also known as PanK),
phosphopantothenoylcysteine synthetase (CoaB), phospho-
pantothenoylcysteine decarboxylase (CoaC), phosphopantetheine
adenylyltransferase (CoaD) and dephospho-CoA kinase (CoaE).
However, in the vast majority of prokaryotes, including M.
tuberculosis, CoaB and CoaC are encoded by a single gene to
produce a fused bifunctional enzyme (CoaBC). Transcriptional
silencing of individual genes of the CoA biosynthetic pathway of
this pathogen identified CoaBC as uniquely bactericidal within
the CoA pathway, highlighting it as a good candidate for drug
discovery12. Nevertheless, the reported inhibitors for this enzyme
are very few in number and almost invariably substrate
mimicking13–15.
CoaBC converts 4′-phosphopantothenate to 4′-phospho-
pantetheine in three steps. First, 4′-phosphopantothenate (PPA)
reacts with CTP to form 4′-phosphopantothenoyl-CMP with the
release of pyrophosphate. This intermediate subsequently reacts
with cysteine to form 4′-phosphopantothenoylcysteine (PPC)
with the release of CMP, with these two steps being catalysed by
CoaB. The product of CoaB is then decarboxylated by CoaC, an
enzyme of the homo-oligomeric flavin-containing decarboxylase
(HFCD) protein family, to 4′-phosphopantetheine. X-ray crystal
structures have been reported for the individual CoaB and CoaC
enzymes in several organisms, including a structure of CoaB from
Mycobacterium smegmatis, a close relative of M.tuberculosis.
However, a structure of a full-length bifunctional CoaBC had not
been determined.
Here we report the structure of the bifunctional CoaBC of M.
smegmatis at 2.5 Å. We identify a previously unknown allosteric
site in CoaB and crucially, we report the discovery of the first M.
tuberculosis CoaBC allosteric inhibitors. Using X-ray crystal-
lography and enzyme kinetic experiments, we define the mode of
binding of one of the inhibitors and show its impact on the
protein structure and function. These results further illustrate the
potential of CoaBC as a drug target in M. tuberculosis.
Results
Overall structure of CoaBC. As the HFCD protein family of
flavin-binding proteins are known to form homo-oligomers16, we
performed native electrospray-ionisation mass spectrometry (ESI-
MS) to investigate the stoichiometry of CoaBC, previously pro-
posed to form a dodecamer16. Both M. tuberculosis CoaBC





















Fig. 1 Coenzyme A biosynthesis pathway. Depiction of the CoA biosynthesis pathway showing all the substrates and products in each biosynthetic step.
Enzymes are circled in orange while pathway intermediates are boxed in blue.
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(MsmCoaBC) (Supplementary Fig. 1b) exclusively exhibited a
dodecameric assembly, with no other oligomeric species observed
in the spectra, which is consistent with a strong interaction
between the subunits of the complex. The dodecamer of
MtbCoaBC was centred around the 56+ charge state, with an
observed mass of 537 kDa, while the dodecamer of MsmCoaBC
was centred around the 52+ charge state, with an observed mass
of 523 kDa. While the MsmCoaBC mass matches the expected
mass including 12 bound flavin mononucleotide molecules,
the MtbCoaBC mass is ~1% higher than the expected mass of
530 kDa, which can be attributed to non-specific binding of sol-
vent molecules or ions to the protein complexes under the soft
ionisation conditions employed.
Structures of a few proteins of the HFCD family have been
determined17–21. All of these structures show either a homo-
trimeric or homo-dodecameric arrangement of the flavin-
containing Rossmann fold with trimers forming at each of the
vertices of the tetrahedron in the case of a dodecameric
arrangement18. However, all of these proteins, unlike CoaBC,
contain only a single functional domain. We solved the structure
of MsmCoaBC (PDB: 6TGV) at 2.5 Å resolution (Fig. 2a), in the
presence of CTP and FMN (Fig. 2b and Supplementary Fig. 2a,
b), using crystals belonging to the H32 space group with an
asymmetric unit containing four protomers forming two CoaBC
dimers. Data collection and refinement statistics are summarised
in (Supplementary Table 1). The final model (residues 2–412)
covers both CoaC and CoaB, but densities for several residues in
three loop regions in CoaB are not observed (residues 290–298,
336–342, 363–376). Nevertheless, all these residues except for 375
and 376, can be seen in the MsmCoaB X-ray crystal structure
(PDB: 6TH2) that we also solved in this work at 1.8 Å. The
N-terminal CoaC ofMsmCoaBC (residues 1–179) forms the same
type of dodecameric arrangement seen in other HFCD family
proteins, such as the peptidyl-cysteine decarboxylase EpiD18, and
it sits at the core of the dodecamer (Fig. 2a, c) with the two
domains connected through a small loop region (residues
180–189) that tightly interacts with both. The active site of CoaC
sits at the interface between two protomers of one CoaC trimer
and a protomer of an adjacent CoaC trimer with the FMN site
facing inwards towards the hollow centre of the dodecamer
(Fig. 3a). A previously described flexible flap that encloses the
reaction intermediate bound to Arabidopsis thaliana CoaC22 is
also observed in some of the protomers, but in an open
conformation (Fig. 2b).
The C-terminal CoaB of MsmCoaBC also displays a Rossmann
fold consistent with several other CoaB structures solved
previously, including both the eukaryotic form, in which CoaB
exists as an individual polypeptide, and the bacterial form where
CoaB is typically fused with CoaC23–25. Each CoaB of
MsmCoaBC (residues 190–414) dimerises with a CoaB belonging
to an adjacent trimer (Fig. 2c). The full protein resembles a
tetrahedron with CoaB dimers positioned at the six edges and
CoaC trimers at the four vertices (Fig. 2a).
The shortest distance between a pair of CoaB and CoaC active
sites is ~30 Å (Fig. 3b). Nevertheless, a flexible loop (residues
362–377) that covers the 4′-phosphopantothenate site, when this
substrate binds to the enzyme23, can be seen in our MsmCoaB
structure, extending away from the active site. A superposition of
our MsmCoaB dimer structure with MsmCoaBC shows the loop
extending towards the CoaC active site (Fig. 3b). This long loop
(15–16 amino acids) is present in all CoaBCs (Supplementary
Fig. 3) and it is possible that it helps channelling the substrate
from the CoaB to the CoaC active site.
The small differences (RMSD= 1.147 Å) in overall structure of
CoaB dimers in the full-length MsmCoaBC and the MsmCoaB
crystal structure solved at 1.8 Å (Supplementary Fig. 4) can be
attributed to artefacts of crystal packing. Similarly, the CoaC structure
does not seem to differ between full-length MsmCoaBC and the
available individual CoaC structures. However, when MsmCoaB
(residues 186–414) is expressed alone, the protein does not dimerise
in solution and is inactive. This contrasts with E. coli CoaB, which
still dimerises and is functional when expressed on its own without
a
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Fig. 2 X-ray crystal structure of FMN and CTP-bound MsmCoaBC. a Full aspect of the dodecameric CoaBC with CoaC represented in teal and CoaB in
gold. b View of a CoaBC dimer with FMN and CTP shown. Each protomer is coloured differently. The CoaC active site flexible flap is highlighted in blue. c In
the left panel, a CoaBC trimer is shown with the CoaC coloured in teal and CoaB in gold. On the right panel dimerisation of two CoaBC trimers is shown
with CoaC coloured in teal or grey for different trimers. Each CoaB forms a dimer with protomers from different trimers.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20224-x ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:143 | https://doi.org/10.1038/s41467-020-20224-x |www.nature.com/naturecommunications 3
the N-terminal CoaC13,26. The CoaB dimer interface is mostly
conserved, but there are clear differences in the dimerisation region
between MsmCoaB and E. coli CoaB that could help to explain the
different observed oligomerisation patterns (Supplementary Fig. 3).
The absence of dimerisation for theMsmCoaB when expressed alone
suggests that the interactions between CoaC and CoaB in
M. smegmatis, and likely all otherMycobacteriaceae, are fundamental
for CoaB dimerisation and activity. This idea is reinforced by the fact
that the residues located at the interface of the two enzymes (CoaB
and CoaC) are well conserved in all Mycobacteriaceae and somewhat
conserved in the sub-order Corynebacterineae, but not outside of this
group (Supplementary Fig. 3).
The CoaB dimerisation region forms a β-sandwich composed
of eight anti-parallel β-strands, related by 2-fold symmetry, that
contacts with the active site (Fig. 3c, d). Comparison of the
MsmCoaB with human CoaB reveals that the human and many
other eukaryotic CoaBs24 possess two extra α-helices and β-
strands involved in the dimerisation interface that help stabilise
the dimer in the absence of CoaC (Supplementary Fig. 5).
The CoaB active site is enclosed by a loop that extends from the
opposing protomer. This loop contains a motif “K-X-K-K”, which
is widely conserved in bacteria (Supplementary Fig. 3), with few
exceptions, and each lysine either interacts directly with the
triphosphate group of CTP or through highly coordinated waters
(Fig. 3c). Also observed is the coordination of a cation by the
triphosphate group and D281 (Fig. 3c and Supplementary Fig. 6).
While magnesium or manganese are the favoured cations for
CoaB activity27, calcium is observed in our structures instead, due
to the high concentration present in the crystallisation condition.
CoaBC is regulated by CoA thioesters. It is known that CoA
biosynthesis is regulated, in many organisms, at the first step of
the pathway, which is catalysed by the enzyme CoaA3.
M. tuberculosis and many other mycobacteria possess a CoaA
(type I PanK) as well as CoaX (type III PanK). However, only the
type I PanK seems to be active based on studies in M. tubercu-
losis28. CoA and its thioesters competitively inhibit E. coli CoaA
by binding to the ATP site, with CoA being the strongest
regulator29,30. Nevertheless, at physiologically relevant levels of
CoA there is only a low level inhibition of CoaA30. It is also
known that M. tuberculosis CoaD, the enzyme that catalyses the
fourth step of the pathway, is competitively inhibited by CoA and
its product dephospho-CoA31,32. However, nothing was known
about the regulation of CoaBC in any organism. We therefore
examined the effect of CoA and several of its thioesters (acetyl-
CoA, malonyl-CoA and succinyl-CoA) on MtbCoaBC activity,
using a coupled enzymatic assay that quantifies the release of
pyrophosphate (EnzChek pyrophosphate assay). Controls were
performed to assess the activity of these compounds against the
two coupling enzymes and the compounds showed an absence of
inhibition at the tested range of concentrations.
Inhibition of CoaB activity by CoA and acyl-CoAs was
observed, with IC50 values ranging from 38 to 148 µM, far below
the predicted intracellular concentrations of acyl-CoAs33, with
succinyl-CoA displaying the highest inhibition (Fig. 4a and
Table 1). To assess the mode of inhibition of CoA and its
thioesters the EnzChek-coupled enzyme assay that measures the
release of pyrophosphate was used to follow the first half of
the reaction while a CMP quantification assay was used for the
second half of the reaction. Competition assays with the three
substrates and acetyl-CoA show a competitive mode of inhibition
relative to CTP and PPA with a Ki of 22.5 and 22.4 µM,
respectively, and non-competitive inhibition for L-cysteine with a




























Fig. 3 Detailed view of MsmCoaBC active sites and MsmCoaB dimerisation interface. a View of CoaC active site with FMN bound. The active site sits
between two protomers of one trimer (gold and pink) and a third protomer from an adjacent trimer (green). Hydrogen bonds are depicted in yellow and
π-interactions are in blue. b Superposition of a CoaB crystal structure in green, with full-length CoaBC (teal) showing the active site flaps (brown) of the
CoaB and CoaC enzymes. c Detailed view of the CTP binding site. Cartoon and residues belonging to each protomer are coloured differently. Hydrogen
bonds and π-interactions are coloured as in b. Important waters are represented as red spheres and calcium as a green sphere. Calcium coordination is
depicted in purple. d CoaB dimerisation interface. Each protomer is coloured as in c.
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structure to confirm the mode of binding, these results suggest
that acyl-CoAs most likely bind to the active site itself, competing
directly with CTP and PPA. Interestingly, both acyl-CoAs,
involved in fatty acid synthesis, as well as those involved in the
TCA cycle, show inhibition of CoaB, with larger fatty acyl chains
showing higher inhibition of CoaB (Fig. 4a).
Identification of CoaB inhibitors using high-throughput
screening. Although the CoA biosynthetic pathway is con-
sidered an attractive target for drug discovery, CoA pathway
inhibitors displaying potent whole cell activity are rare and the
few CoaBC inhibitors that have been reported to date are in
majority substrate mimicking13,34.
In order to identifyMtbCoaBC inhibitors, we have conducted a
high-throughput screen of 215,000 small molecules targeting
CoaB activity. To do this, an end-point pyrophosphate quanti-
fication assay was used (Biomol Green). The most potent hits
identified were compounds 1a and 2a with IC50 values of 9 and
3.1 µM, respectively (Fig. 5 and Supplementary Table 2),
originating from two different but related chemical scaffolds. A
search was then performed for commercially available analogues.
Testing of analogues of the initial hits resulted in the
identification of more potent compounds with sub-micromolar
IC50 values (Table 1 and Supplementary Table 2, Figs. 5, 6a and
Supplementary Fig. 7). Of these, compounds 1b and 2b (Figs. 5,
6a and Table 1), with IC50 values of 0.28 and 0.08 µM,
respectively, were identified as the most potent of the two
chemical series and therefore were selected for further work.
Selectivity and elucidation of the mode of inhibition. Following
the identification of potent MtbCoaB inhibitors we went on to
determine their activity against human CoaB (HCoaB) and
MsmCoaBC. Control experiments were first performed to assess
compound activity against the two coupling enzymes of the
EnzChek assay and the compounds were found to be inactive at
100 µM. The IC50 values for the most active compounds against
MtbCoaB were re-determined with this assay and the values
obtained were in line with the primary screening assay (Supple-
mentary Table 2). Both compounds were also found to be highly
selective for mycobacterial enzymes showing activity for
MsmCoaBC in a similar range to what was observed for
MtbCoaBC with IC50 values of 0.26 and 0.18 µM, respectively,
and were two orders of magnitude less active for the human CoaB
(HCoaB) with IC50 values of 122 and 60.4 µM, respectively
(Table 1 and Supplementary Fig. 7).
Competition experiments were then performed between the
three CoaB substrates and the two most potent compounds of
each chemical series (1b and 2b) to determine the mode of
inhibition. Compound 1b showed uncompetitive inhibition for all
CoA
IC50 = 148 ± 11 μM
Acetyl-CoA
IC50 = 121 ± 9 μM
Malonyl-CoA
IC50 = 48 ± 3 μM
Succinyl-CoA
IC50 = 38 ± 2 μM
a b
Fig. 4 Regulation of MtbCoaBC by CoA and CoA thioesthers. a Inhibition of MtbCoaBC by CoA, acetyl-CoA, malonyl-CoA and succinyl-CoA.
b Lineweaver–Burk plots showing the effect of varying the concentration of each substrate in the presence of different concentrations of acetyl-CoA. Data
are presented as average values of three independent experiments with ± SD. Source data are provided as a source data file.
Table 1 Inhibition of MtbCoaB domain by CoA, CoA
thioesters and MtbCoaB, MsmCoaB and HCoaB by the most







CoA 148 ± 11
AcCoA 121 ± 9
MlCoA 49 ± 3
SucCoA 38 ± 2
1b 0.28 ± 0.05 122 ± 22 0.26 ± 0.02
1c 4.6 ± 0.4
2b 0.08 ± 0.01 60 ± 7 0.18 ± 0.02
2c 0.41 ± 0.03
2d 0.54 ± 0.06
2e 3.0 ± 0.2
IC50 values determined using the EnzChek pyrophosphate assay are shown.
Data are presented as average values of three independent experiments with ± SD.
Table 2 Inhibitor constants of acetyl-CoA, compounds 1b
and 2b for the three CoaB substrates.
Inhibitor Variable
substrate
Ki (µM) Inibition type#
AcCoA CTP 22.5 ± 1.7 C
PPA 22.4 ± 1.4 C
L-cysteine 62.1 ± 2.0 NC
1b CTP *0.222 ± 0.012 UC
PPA *0.078 ± 0.005 UC
L-cysteine *0.181 ± 0.008 UC
2b CTP 0.093 ± 0.018 Mixed
PPA *0.062 ± 0.004 UC
L-cysteine *0.055 ± 0.003 UC
*For uncompetitive inhibitors αKi product is shown.
#Abbreviations: C competitive inhibition, NC non-competitive inhibition, UC uncompetitive
inhibition.
Data are presented as average values of three independent experiments with ± SD.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20224-x ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:143 | https://doi.org/10.1038/s41467-020-20224-x |www.nature.com/naturecommunications 5
substrates with a αKi of 0.222, 0.078 and 0.181 µM, respectively,
for CTP, PPA and L-cysteine (Fig. 6b and Table 2), consistent
with the compound binding preferentially when the three
substrates are bound. Compound 2b shows mixed inhibition
relative to CTP with a Ki of 0.093 µM and uncompetitive
inhibition for PPA and L-cysteine with a αKi, respectively, of
0.062 and 0.055 µM (Fig. 6c and Table 2). It is known that CoaB
forms the phosphopantothenoyl-CMP intermediate in the
absence of L-cysteine35 and, due to spatial constraints, it is likely
that cysteine can only bind at the active site after the release of
pyrophosphate. The data is therefore consistent with compound
1b preferentially binding after L-cysteine enters the active site, for
the last step of catalysis and the formation of 4′-phosphopan-
tothenoylcysteine and CMP. However, compound 2b shows a
mixed inhibition for CTP, reflecting a slightly different mechan-
ism of action. These results obtained for both compounds suggest
the existence of an allosteric site in the CoaB moiety of
MtbCoaBC.
Structural basis for inhibition of CoaB by allosteric inhibitors.
In order to elucidate the binding mode of compound 1b we used
a truncation of the MsmCoaB (residues 187–414) that was pre-
viously crystallised before by others in the presence of CTP (PDB:
4QJI) at 2.65 Å resolution. Screening for crystallisation conditions
allowed us to find a different CTP containing condition that gave
excellent resolution (1.8 Å). Comparison of this structure with the
full-length MsmCoaBC (Supplementary Fig. 4) showed only
minor differences that can be attributed to crystal packing. Hence
this crystallisation system could be used to validate CoaB inhi-
bitors binding outside of the CTP site.
MsmCoaB was co-crystallised with CTP in the absence of
compound 1b and overnight soaking of the crystals with this
compound was performed. A co-crystal structure of MsmCoaB
with compound 1b (PDB: 6THC) was obtained and showed that
the compound was bound to a site at the dimer interface of CoaB,
in a deep cavity that is occluded when the compound is absent
(Fig. 7a, b and Supplementary Fig. 8). Each CoaB dimer contains
two of these sites, which are formed by a sandwich of eight β-
strands and a long loop that contains the conserved “K-X-K-K”
motif. This site opens to the active site and the inhibitor also
contacts with D281 that is involved in the coordination of the
cation (Fig. 7c). Several residues are shared between the allosteric
site and the active site and these include R207, N211, A280, D281
I292, K293 and K294. The opening/closing of this cryptic
allosteric site is mediated by the side chain of R207 of the
opposing protomer (Fig. 7d) that moves 5.5 Å at the furthest
point and, to a smaller extent, by the side chain of F282 that
moves 2 Å. R207 has previously been shown to be critical for the
second half of the reaction catalysed by CoaB, the conversion of
the 4′-phosphopantothenoyl-CMP intermediate to PPC, with
almost no conversion of the intermediate to PPC detected when
this arginine is mutated to glutamine35. Given the position of this
arginine, it is likely that it is involved in the binding of cysteine.
Despite the absence of a crystal structure with cysteine, kinetic
data showing uncompetitive inhibition with cysteine is consistent
with this.
This allosteric site is comprised of a large group of
hydrophobic residues (I209, F282 and L304 of protomer A and
L203, I292, P299 and I302 of protomer B) many of which form
hydrophobic interactions with compound 1b (Fig. 7c). Several π-
interactions between the compound and the protein are also
observed and involve the backbone of D281 and the side chain of
F282 of protomer A and R207 of protomer B (Fig. 7d). Hydrogen
bond interactions are formed with D281 and F282 of protomer A
and R207 of protomer B. Water-mediated interactions are also
observed for a group of residues that sit at the outer edge of the
site (L203, H286 and D303) that is formed exclusively by
protomer B (Fig. 7c).
We propose that upon binding of L-cysteine, the R207 side chain
moves towards the active site, and is likely involved in stabilising/
orienting L-cysteine to attack the phosphopantothenoyl-CMP
intermediate. This movement opens the allosteric site, which allows
binding of allosteric inhibitors to the newly created cavity. The
allosteric inhibitors will then stabilise the enzyme in its substrate-
bound state with the position of R207 becoming locked by several
hydrogen bonds with the side chain of D281 of protomer A, the
backbone carbonyl group of I292 and the side chain of D204 of
protomer B, but also by the π-interactions with the compound
(Fig. 7c). The residues around this site and crucially R207 are
conserved across many microorganisms, suggesting that this
allosteric site is present in most, if not all bacterial CoaBCs
(Supplementary Figs. 3, 9a). Interestingly, even though overall
sequence identity is very low between the human CoaB and
MsmCoaB (22%), the human enzyme also contains an arginine
equivalent to R207 and a roughly similar interface with several
conserved residues, but there are stark differences in the relative
position of the residues at this site between the two enzymes
(Supplementary Fig. 9b) which can explain the observed large
differences in potency of the inhibitors between the human and
mycobacterial enzymes.
While we were not able to obtain co-crystal structures with
other inhibitors, in silico docking helped to provide a possible
explanation for the structure–activity relationship observed for













































Fig. 5 Chemical structures of the main compounds of series 1 and 2.
Chemical structures of the initial hits (1a and 2a) and most potent
compounds for series 1 and 2.
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compound 1b, the most potent inhibitor of series one, was almost
identical to that observed in the co-crystal structure (Supple-
mentary Fig. 10a), and the analogues for which docking was
performed adopted a similar binding pose. The lower activity of
compound 1a relative to compound 1b could be explained by the
loss of water-mediated hydrogen bonds (Fig. 7c and Supplemen-
tary Fig. 10b), while the lower activity of compound 1c could be
explained by the loss of the carbonyl group which faces a highly
electropositive area of the protein (Supplementary Fig. 10c).
Compound 2b is predicted to form direct hydrogen bonds at the
bottom of the allosteric site, similar to those formed by
compound 1b, but also to interact directly with L203 and
H286, forming extra hydrogen bonds at the top of the allosteric
site (Fig. 8). For compound 1b the interactions at the top of the
site are water mediated (Fig. 7c). This could explain the higher
potency of compound 2b. Compounds 2c and 2d are also
predicted to form direct hydrogen bond interactions at the top of
the allosteric site, but the interactions at the bottom of the site are
not as favourable due to the presence of extra hydroxyl groups
(Supplementary Fig. 10d–f). The remaining compounds in series
two, which have fewer hydroxyl groups and/or hydroxyl groups
in different positions, lose the ability to form hydrogen bonds,
consistent with the weaker inhibitory effect observed (Supple-
mentary Table 2). The observed loss of activity of these
compounds demonstrates the importance of the catechol group
for binding in these two chemical series.
Screening of CoaBC inhibitors against M. tuberculosis. The
in vitro whole cell activity of the compounds was further eval-
uated by their ability to inhibit M. tuberculosis growth on dif-
ferent carbon sources. None of the compounds exhibited activity
in media containing glycerol or cholesterol as the main carbon
source (Table 3). We then tested whether the lack of inhibitory
activity could be attributed to the presence of BSA by determining
the whole cell activity of the three most potent inhibitors against
M. tuberculosis in GAST/Fe minimal media. All the tested com-
pounds exhibited moderate to low activity in this media with
compound 2b displaying the best activity of the five (Table 3).




IC50 = 0.28 ± 0.05 μM
2b
IC50 = 0.08 ± 0.01 μM
c
Fig. 6 Inhibition of MtbCoaBC by compounds 1b and 2b. a Dose response profiles and chemical structure of compounds 1b and 2b is shown.
b, c Lineweaver–Burk plots respectively showing the effect of varying concentrations of compounds 1b and 2b in the presence of varying concentrations
of CTP, PPA and L-cysteine. Data are presented as average values of three independent experiments with ± SD.
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CoaBC inducible knockdown12 in GAST/Fe minimal media to
determine whether the observed anti-mycobacterial activity was
related to CoaBC inhibition. However, incremental silencing of
CoaBC did not sensitise M. tuberculosis further to compounds 1b
and 2b, suggesting that the activity of the compounds is not on
target. We further tested if the compounds could permeate M.
tuberculosis cell envelope and reach the cytoplasm. Compound 1b
exhibited no depletion from the media indicating a lack of uptake
or rapid efflux (Supplementary Table 3). Compound 2b, in con-
trast, exhibited complete depletion from the media but accumu-
lated in M. tuberculosis to levels that accounted for less than 2%
of the amount consumed (Supplementary Table 3), indicative of
its likely intrabacterial metabolism36–39. These results explain the
observed differences in potency between the enzymatic assay and
whole cell activity and shows that they are related to low com-
pound permeation/high efflux for 1b and metabolism in the case
of 2b.
Discussion
CoA is an essential co-factor ubiquitous across all domains of life.
For many years, this pathway has been considered an attractive
drug target to develop new antibiotics against a wide range of
pathogens including M. tuberculosis40. Furthermore, the recent
identification of CoaBC as a key fragility point in the CoA




















Fig. 7 MsmCoaB X-ray structure showing the cryptic allosteric site. CoaB with the cryptic allosteric site closed (a) and opened conformation (b) with
compound 1b (pink) bound. c Detailed view of the allosteric site with compound 1b (yellow) bound. The individual protomers of the CoaB dimer are
coloured in green or pink. Hydrogen bonds are depicted in red, π-interactions are in grey and hydrophobic interaction in green. Important waters are
represented as red spheres and calcium as a green sphere. Calcium coordination is depicted in purple. d Gating mechanism of the cryptic allosteric site
showing the movement of R207 with the closed conformation in yellow and the open conformation in pink. An E. coli structure (PDB: 1U7Z) with the
4′-phosphopantothenoyl-CMP (purple) intermediate bound is superimposed.
Table 3 Minimum inhibitory concentration (MIC) values of







1b >250 >250 125
1c >250 ND 125
2b >250 >250 50
2c >250 >250 125
2d >250 >250 >250
2e >250 ND 125
ND Not determined.





Fig. 8 Docking of compound 2b into MsmCoaB showing the highest-
scoring pose. Hydrogen bonds are shown in red. The individual protomers
of the CoaB dimer are either coloured in green or pink.
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identity with the human CoaB (25%), makes this enzyme a highly
attractive drug discovery target.
While a structure of an individual mycobacterial CoaB was
available, we were aware that the many questions remaining at
the start of this work about the organisation and regulation of this
bifunctional enzyme could have significant implications for drug
discovery. We therefore set out to obtain a full-length structure of
a mycobacterial CoaBC and we successfully solved the
MsmCoaBC structure, which shares very high sequence identity
with the M. tuberculosis orthologue (86% full-length, 84% CoaB
enzyme) and hence is a valuable tool for studying M. tuberculosis
CoaBC. The organisation of CoaBC is similar to other HFCD
family proteins18 but unique in the sense that it contains more
than one domain and highlights how the arrangement of the
fused enzymes is essential for mycobacterial CoaB dimerisation
and function. This fused arrangement might also help to channel
the CoaB product to the CoaC active site more effectively. The
human CoaB and other eukaryotic orthologues form stable
dimers due to the extra dimerisation region (Supplementary
Fig. 5), but it is also known in yeast that the entire CoA pathway
assembles into a metabolon centred on CoaC41,42 (known as
CAB3). This hints that close proximity between the different
active sites of the CoA enzymes is desirable and that substrate
channelling of products and substrates between different enzymes
might be important in this pathway. It is not clear at this point if
such an arrangement for the entire CoA pathway is also present
in bacteria.
Regulation of the CoA biosynthesis pathway was known to
occur for other enzymes of the pathway through feedback inhi-
bition by CoA, but no information was available for CoaBC. We
demonstrate that both CoA, as well as several CoA thioesters,
regulate CoaBC by inhibiting CoaB activity, and that these
molecules act competitively for CTP and PPA and non-
competitively for L-cysteine. This is consistent with these mole-
cules binding to the CoaB active site but not to the L-cysteine
sub-site. CoA and acyl-CoAs inhibit both CoaA and CoaD
enzymes to varying extents30,32,43. However, the inhibitory effect
of CoA and its thioesters on the activity of these enzymes is lower
when compared to what we observed in CoaBC and consequently
the impact of the intracellular level of these molecules will be
predominant in CoaBC. We therefore report a new and impor-
tant mechanism of regulation of “de novo” CoA biosynthesis,
mediated by the action of CoA thioesters on CoaBC. Since the
reported intracellular levels of these molecules33 are normally
above the observed IC50, the activity of CoaBC is highly inhibited.
This correlates well with previous work showing that “de novo”
CoA biosynthesis closely matches dilution due to cell division44.
However, the data for intracellular concentrations of CoA and
CoA thioesters, as well as CoA half-life was not obtained for
mycobacteria, and both interspecies differences along with var-
iations in growth conditions may affect these conclusions.
Although the CoA pathway and CoaBC have been the subject
of many drug discovery efforts, few non-substrate-mimicking
inhibitors of CoaBC have been reported13. Our work identifies
two related chemical scaffolds that potently inhibit the activity of
the CoaB moiety of MtbCoaBC through a cryptic allosteric site
that sits in the dimer interface region of the CoaB enzyme. This
site is closed in the CTP-bound structure, by the side chain of
R207 a residue known to be involved in the second and final step
of the reaction catalysed by CoaB – the conversion of the 4’-
phosphopantothenoyl-CMP intermediate to PPC35. Considering
the role of this residue in the final step of product formation and
that compound 1b shows uncompetitive inhibition relative to all
CoaB substrates, we propose that the opening of this site occurs
upon binding of the final substrate L-cysteine. Currently it is not
clear whether this allosteric site is exploited by a natural ligand, as
we were unable to identify such a biomolecule. Nevertheless, the
conservation of residues at this site, across a variety of bacteria,
indicates that this feature might be common to many, if not all,
bacterial CoaBs.
The different mechanism of inhibition between compounds 1b
and 2b in relation to CTP is difficult to explain without a
structure of a complex between CoaB and 2b and docking does
not offer further insight. However the observed mixed inhibition
model for CTP in the case of compound 2b might be due to the
fact that this compound is more sterically bulky than 1b and
slight movements of residues at the bottom of the allosteric site
(A280 and D281) are required to accommodate the compound
and that these movements are blocked in the crystal. This cor-
relates well with the fact that no crystal structure of compounds
of series 2 could be obtained even when soaking at high
concentrations.
Drug discovery against M. tuberculosis is rich in examples of
compounds with potent activity against an essential enzyme but
with a complete lack of whole cell activity due to the impermeable
cell wall of this organism, efflux pumps, target modification
enzymes and extensive capacity to metabolise compounds45. The
modest in vitro whole cell activity displayed by the CoaB inhi-
bitors reported in this work is off target and relates to the char-
acteristics of M. tuberculosis with compound 1b being unable to
reach the cytoplasm and 2b suffering metabolism. Nevertheless,
the biochemical and structural data described herein further
validate CoaBC as a promising anti-tubercular drug target by
showing an allosteric site that can be targeted by potent and
selective inhibitors.
Methods
Cloning and protein purification. M. tuberculosis and M. smegmatis coaBC genes
were amplified from genomic DNA ofM. tuberculosis H37Rv strain, obtained from
ATCC (ATCC25618D-2), using the primers MtbBC28S-F and MtbBC28S-R
(Supplementary Table 4), and genomic DNA of M. smegmatis mc2 155, using the
primers MsmBC28S-F and MsmBC28S-R (Supplementary Table 4), and cloned
into a pET28a vector (Novagen), modified to include an N-terminal 6xHis-SUMO
tag. The M. smegmatis coaB construct was obtained from the Seattle Structure
Genomics Center for Infectious Disease. An E. coli optimised Human CoaB gene
was ordered from Thermofisher and cloned into pHAT446 using NcoI and HindIII
restriction sites. The same protein purification protocol was used for both M.
tuberculosis and M. smegmatis CoaBC constructs.
E. coli BL21(DE3) containing pET28aSUMO-CoaBC was grown in 2XYT media
at 37 °C until an O.D.600= 0.6. IPTG was then added to a final concentration of 0.5
mM and the temperature changed to 18 °C for 18–20 h. Cells were then harvested
by centrifugation, re-suspended in 50 mM TRIS pH 8.0, 250 mM NaCl, 20% (w/v)
glycerol, 20 mM imidazole, 5 mM MgCl2 with protease inhibitors tablets (Roche)
and DNAseI (Sigma). Cells were lysed with an Emulsiflex (Avestin) and the
resultant cell lysate was centrifuged at 27,000x g for 30 min to remove cell debris.
Recombinant CoaBCs were purified with a HiTrap IMAC Sepharose FF column
(GE-Healthcare), equilibrated with 50 mM TRIS pH 8.0, 250 mM NaCl, 20% (w/v)
glycerol and 20 mM imidazole. Elution was performed in the same buffer with
500 mM imidazole. Protein was dialysed in 25 mM TRIS pH 8 and 150mM NaCl
and the SUMO tag was cleaved overnight at 4 °C by adding Ulp1 Protease at a
1:100 ratio. CoaBC was concentrated and loaded on a Superdex 200 column
equilibrated with 25 mM TRIS pH 8.0, 150 mM NaCl. Fraction purity was
determined by SDS-page and the purest fractions were pooled, concentrated to
~10 mgmL−1 for MtbCoaBC and 30mgmL−1 for MsmCoaBC, flash frozen in
liquid nitrogen and stored at −80 °C.
E. coli BL21(DE3) containing the M. smegmatis CoaB construct with a
N-terminal non-cleavable 6xHis tag was grown and harvested as above and re-
suspended in 20 mM HEPES pH 7.0, 500 mM NaCl, 20 mM imidazole, 5 mM
MgCl2 with protease inhibitors tablets (Roche) and DNAseI (Sigma). Cells were
lysed with an Emulsiflex (Avestin) and cell lysate was centrifuged at 27,000x g for
30 mins to remove cell debris. Recombinant M. smegmatis CoaB was purified with
a HiTrap IMAC Sepharose FF column (GE-Healthcare), equilibrated with 20 mM
HEPES pH 7.0, 500 mM NaCl and 20 mM imidazole. Elution was carried out in the
same buffer with 500 mM imidazole. Protein was concentrated and loaded on a
Superdex 200 column equilibrated with 20 mM HEPES pH 7.0 and 500 mM NaCl.
Fraction purity was assessed by SDS-page and the purest fractions were pooled
concentrated to 22 mgmL−1, flash frozen in liquid nitrogen and stored at −80 °C.
E. coli BL21(DE3) containing a human CoaB construct with a cleavable N-
terminal 6xHis tag was grown and harvested as above and re-suspended in 50 mM
TRIS pH 8.0, 250 mM NaCl, 20 mM imidazole, 5 mM MgCl2 with protease
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inhibitors tablets (Roche) and DNAseI (Sigma). Cells were lysed using a sonicator
and cell lysate was centrifuged at 27,000x g for 30 mins to remove cell debris.
Recombinant Human CoaB was purified with a HiTrap IMAC Sepharose FF
column (GE-Healthcare), equilibrated with 50 mM TRIS pH 8.0, 250 mM NaCl
and 20 mM imidazole. Elution was performed in the same buffer with 300 mM
Imidazole. Protein was dialysed in 25 mM TRIS pH 8 and 150 mM NaCl and the
His tag was cleaved overnight at 4 °C by adding TEV Protease at a 1:50 ratio.
Human CoaB was concentrated and loaded on a Superdex 200 column equilibrated
with 25 mM TRIS pH 8.0, 150 mM NaCl. Fraction purity was determined by SDS-
page and the purest fractions were pooled, concentrated to ~10 mgmL−1, flash
frozen in liquid nitrogen and stored at −80 °C. SDS-PAGE images showing the
pure enzymes are given in (Supplementary Fig. 11).
Native mass spectrometry. Spectra were recorded on a Synapt HDMS mass
spectrometer (Waters) modified for studying high masses. MtbCoaBC and
MsmCoaBC were exchanged into NH4OAc (500 mM, pH 7.0) solution using Micro
Bio-Spin 6 chromatography columns (Bio-Rad). A sample volume of 2.5 μL was
injected into a borosilicate emitter (Thermo Scientific) for sampling. Instrument
conditions were optimised to enhance ion desolvation while minimising dis-
sociation of macromolecular complexes. Typical conditions were capillary voltage
1.8–2.0 kV, sample cone voltage 100 V, extractor cone voltage 1 V, trap collision
voltage 60 V, transfer collision voltage 60 V, source temperature 20 °C, backing
pressure 5 mbar, trap pressure 3–4 × 10−2 mbar, IMS (N2) pressure 5–6 × 10−1
mbar and TOF pressure 7–8 × 10−7 mbar. Spectra were calibrated externally using
caesium iodide. Data acquisition and processing were performed using MassLynx
4.1 (Waters).
Crystallisation. For both full-length MsmCoaBC and MsmCoaB alone, the crys-
tallisation screens and optimisation were performed at 18 °C using the sitting-drop
vapour diffusion method. For CoaBC 300 nL of pure protein at 30 mgmL−1, pre-
incubated with 3 mM CTP and 10mMMgCl2, was mixed in 1:1 and 1:2 (protein to
reservoir) ratio with well solution using a mosquito robot (TTP labtech). Initial
conditions were obtained in the Classics lite crystallisation screen (Qiagen), solu-
tion 1. Crystals obtained in this condition diffracted poorly, therefore several
rounds of optimisation were performed. The final optimised condition consisted of
0.1 M BisTris pH 6.5, 10 mM CoCl2 0.8 M 1,6-hexanediol. Crystals appeared after
three days in both conditions. A cryogenic solution was prepared by adding
ethylene glycol up to 30% (v/v) to the mother liquor. Crystals were briefly trans-
ferred to this solution, flash frozen in liquid nitrogen and stored for data collection.
ForMsmCoaB, 200 nL of pure protein at 22–24 mgmL−1 with 10 mM CTP was
mixed in 1:1 ratio with well solution using a Phoenix robot (Art Robbins). Crystals
were obtained in Wizards classics III&IV (Rigaku) solution G4 consisting of 20%
(w/v) PEG 8000, 0.1 M MES pH 6.0 and 0.2 M calcium acetate. Crystals appeared
after 2 days.
To obtain ligand-bound structures, soaking was performed using the hanging-
drop vapour diffusion method as follows: 2 µL of a solution containing 20% (w/v)
PEG 8000, 0.1 M MES pH 6.0, 0.2 M calcium acetate, 0.25 M NaCl 10% (v/v)
DMSO and 1–5 mM inhibitors was left to equilibrate against 500 µL of reservoir
solution for 3 days. Crystals were then transferred to the pre-equilibrated drops and
incubated for 24 h. A cryogenic solution was prepared by adding
2-methyl-2,4-pentanediol up to 25% (v/v) to mother liquor. Crystals were briefly
transferred to this solution, flash frozen in liquid nitrogen and stored for data
collection.
Data collection and processing. The data sets were collected at stations I02 and
I03 at Diamond Light Source (Oxford, UK). The diffraction images were processed
with AutoPROC47 using XDS48 for indexing and integration with AIMLESS49 and
TRUNCATE50 from CCP4 Suite51 for data reduction, scaling and calculation of
structure factor amplitudes and intensity statistics.
Structure solution and refinement. MsmCoaB and MsmCoaBC structures were
solved by molecular replacement using PHASER52 from the PHENIX software
package53. For MsmCoaB, the atomic coordinates of MsmCoaB structure (PDB:
4QJI) were used as a search model. Ligand-bound structures were solved using our
highest resolution MsmCoaB apo form structure (PDB: 6TH2). For MsmCoaBC,
atomic coordinates of Arabidopsis thaliana CoaC (PDB: 1MVL)22 and our highest
resolution CoaB structure (PDB: 6TH2) were used as search models. Model
building was done with Coot54 and refinement was performed in PHENIX53.
Structure validation was performed using Coot and PHENIX tools53,54. All figures
were prepared using Pymol (The PyMOL Molecular Graphics System, Version 2.0
Schrödinger, LLC.) and ligand interactions calculated with Arpeggio55.
High-throughput screening. Potential inhibitors of MtbCoaBC were assessed at
room temperature using a PHERAstar microplate reader (BMG Labtech). Pyr-
ophosphate produced by CoaB was converted to two molecules of inorganic
phosphate using a pyrophosphatase. Phosphate was then detected using the
BIOMOL® Green reagent (Enzo Life Sciences), which when bound to phosphate
absorbs light at 650 nm. An end-point assay was carried out in clear, flat-bottom,
polystyrene, 384-well plates (Greiner) in an 50 µL reaction volume containing
100 mM TRIS, pH 7.6, 1 mM MgCl2, 1 mM TCEP, 0.03 U/mL pyrophosphatase,
2 µM CTP, 40 µM L-cysteine, 30 µM PPA and 30 nM MtbCoaBC. Assays were
performed by adding 25 µL of a 2-times concentrated reaction mixture containing
all components with the exception of the enzymes to all wells, and the reactions
started by adding 25 µL of a 2-times concentrated enzyme mixture. The reaction
was carried out for 2 h at room temperature, before 50 µL of BIOMOL® Green
reagent was added and incubated for a further 20 min prior to reading.
Inorganic pyrophosphatase-purine nucleoside phosphorylase PNP-PPIase
assay. The commercially available EnzChek pyrophosphate assay kit (E-6645)
(Life Technologies) was used for this assay. The final reaction composition used
was 0.03 U/mL inorganic pyrophosphatase, 1 U/mL purine nucleoside phosphor-
ylase, 1 mM MgCl2, 200 µM MESG, 100 mM TRIS pH 7.5, 1 mM TCEP, 2%
DMSO, 32 nM MtbCoaBC or MsmCoaBC, 125 µM CTP, 125 µM PPA, 500 µM L-
cysteine, and various concentrations of compounds being tested for inhibition, all
prepared from DMSO stock solutions (compounds of series one and two) or water
(CoA and CoA thioesters). In the assays with HCoaB an enzyme concentration of
1 µM was used instead. Controls were performed to assess the activity of all the
compounds tested in this work against the two coupling enzymes and the com-
pounds showed an absence of inhibition at the tested range of concentrations.
Assays were performed on either a CLARIOstar or PHERAstar microplate reader
(BMG Labtech) in 96-well plates (Greiner). A substrate mixture containing the
substrates and the inhibitor was pre-incubated at 25 °C for 10 min. An enzyme
solution was prepared and separately pre-incubated at 25 °C for 10 min. The
reaction was initiated by the addition of the substrates to the solution containing
the enzyme to a final volume of 75 µL. Enzymatic activity was monitored by
following the absorbance at 360 nm for 30 min (100 cycles/20 s each cycle) and
only the steady-state region of the assay was used for data analysis. Assays were
performed in triplicates, including a negative control (lacking PPA) and a positive
control (lacking inhibitor).
Competition assays to assess the first half of the CoaB enzymatic reaction were
performed using the same conditions but with variable substrate concentrations
(31.25, 62.5, 125, 250 and 500 µM for CTP and PPA.
CMP quantification assay. To assess the second half of the CoaB enzymatic
reaction the release of CMP was monitored using an I-Class UPLC (waters). The
75 µL enzymatic reactions contained 1 mM MgCl2, 100 mM TRIS pH 7.5, 1 mM
TCEP, 2% DMSO, 32 nM MtbCoaBC, 125 µM CTP, 125 µM PPA, variable con-
centrations of L-cysteine (31.25 µM, 62.5 µM, 93.75 µM 125 µM and 250 µM), and
various concentrations of compounds 1b, 2b (prepared from DMSO stocks) and
acetyl-CoA. Reactions were incubated at 25 °C and stopped by adding 5 µL of
EDTA to a final concentration of 20 mM at 5 min intervals for a period of 15 min.
120 µL of mobile phase solvent A (0.1% formic acid in water) was added to each of
the reactions and 10 µL of every reaction were injected into an Acquity UPLC HSS
T3 column, 2.1 mm diameter, 150 mm length and with a particle size of 1.8 µm
(Waters) and eluted using a gradient elution consisting of Mobile Phase A: 0.1%
formic acid in water and mobile phase B: 0.1% formic acid in 100% acetonitrile for
4 min. The absorbance was monitored at 280 nm using a photodiode array (PDA)
detector (Waters). All reactions were carried out in triplicate.
M. tuberculosis strains and MIC measurements. MIC determination for
M. tuberculosis H37RvMA was performed as previously described56 in the following
media: 7H9/ADC/glycerol (4.7 g/L Difco Middlebrook 7H9 base, 100mL/L Mid-
dlebrook albumin (BSA)-dextrose-catalase (ADC) Difco Middlebrook, 0.2% glycerol
and 0.05% Tween-80), 7H9/Cholesterol/Tyloxapol (4.7 g/L 7H9 base, 0.81 g/L NaCl,
24 mg/L cholesterol, 5 g/L BSA fraction V and 0.05% Tyloxapol) and GAST/Fe
(0.3 g/L of Bacto Casitone (Difco), 4.0 g/L of dibasic potassium phosphate, 2.0 g/L of
citric acid, 1.0 g/L of L-alanine, 1.2 g/L of magnesium chloride hexahydrate, 0.6 g/L
of potassium sulfate, 2.0 g/L of ammonium chloride, 1.80 ml/L of 10 N sodium
hydroxide, 10.0 mL of glycerol 0.05% Tween-80 and 0.05 g of ferric ammonium
citrate adjusted to pH 6.6).
M. tuberculosis CoaBC knockdown and on-target activity. M. tuberculosis
H37RvMA and its coaBC Tet-OFF conditional knockdown derivative12 were
grown in Difco Middlebrook 7H9 broth (BD) supplemented with Middlebrook
albumin-dextrose-catalase (ADC) enrichment (BD), 0.2% glycerol (Sigma-Aldrich)
and 0.05% Tween-80, unless otherwise indicated. Hygromycin and kanamycin
were used at final concentrations of 50 μg/mL and 25 μg/mL, respectively, and
pantethine (Sigma-Aldrich) supplementation was included at 2.5 mg/mL where
required. The anhydrotetracycline (ATc) inducer was used at concentrations up to
200 ng/mL in order to transcriptionally silence coaBC in the Tet-OFF hypomorph.
The minimum inhibitory concentrations (MIC99) of the compounds were
determined by measuring fluorescence output using Alamar Blue, as previously
described (Singh et al.56). Briefly, 2-fold serial dilutions of compound were
inoculated with a suspension ofM. tuberculosis at a cell density of ~105 CFU/mL in
a 96-well microtiter plate and incubated at 37 °C for 10 days, following which 10 μL
Alamar Blue solution was added and the plates were incubated for a further 24 h.
Fluorescence as an indication of growth was measured using a SpectraMax i3x
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Multi-Mode Microplate Reader (Molecular Devices) in bottom-reading mode with
excitation at 544 nm and emission at 590 nm.
Mycobacterium tuberculosis compound uptake. M. tuberculosis H37Rv was
grown to OD580 1 in Middlebrook 7H9 supplemented with 0.2% glucose and
0.2% glycerol. One mL was added to each nylon Durapore 0.22 μm membrane
filter. Bacteria-laden filters were placed atop Middlebrook 7H11 agar supple-
mented with 0.2% glycerol and 10% OADC, incubated at 37 °C for 1 week to
expand the biomass, and transferred to lay atop a reservoir containing 7H9
medium with 0.2% glucose and 0.2% glycerol (no tyloxapol) and 10 μM of test
agent. After 24 h at 37 °C, bacteria-laden filters were plunged into 1 mL 40:40:20
methanol:acetonitrile:water pre-cooled to −20 °C and lysed in a bead beater
while spent media was reserved for extraction and analysis with cell lysates. Both
cell lysates and spent media were mixed with equal volumes of 50% acetonitrile,
0.2% formic acid for mass spectrometry in positive and negative ion mode as
previously described57.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Coordinates and structure factors related to this work have been deposited in the PDB
with accession numbers: 6TGV, 6TH2 and 6THC. The source data for Tables 1, 2 and
Figs. 4, 6 and Supplementary Fig. 7 are provided as a source data file. Other data are
available from the corresponding authors upon reasonable request. Source data are
provided with this paper.
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